NIH: Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development and validation of sample sparing assays that can be applied for studying the human immune system in health and disease.

For this funding opportunity, budgets may be requested up to $0.85M direct costs per year which includes a limit on the budget for the Infrastructure and Opportunity Fund of $0.5M direct costs per year, and a limit on the U24 research project of $0.35M direct costs per year. Up to 5 years.

Due date: July 30, 2019, LOI 30 days prior

For more information: